share_log

首药控股(688197.SH):ALK抑制剂康太替尼颗粒(CT-707)新药上市申请获得受理

Shuoyao Holdings (688197.SH): The new drug application for the ALK inhibitor cantaanib granules (CT-707) has been accepted.

Gelonghui Finance ·  Oct 22, 2024 17:19

On October 22, GeLongHui announced that Shouyao Holdings (688197.SH) recently received the "Acceptance Letter" issued by the National Medical Products Administration. The company's independently developed Kangtai tinib granules (CT-707, applied commodity name: Shouyaoze) as a single drug is suitable for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) patients with anaplastic lymphoma kinase (ALK) positive new drug listing application (NDA) has been accepted.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment